Published prospective cohort showed durable responses and manageable safety in patients with HCC following prior immunotherapy Median overall survival of 12.3 months in a heavily pretreated population with poor prognostic features, including ALBI grade 2 liver function Agenus Inc. (Nasdaq: AGEN) , a leader in immuno-oncology innovation, today announced the publication of Phase 1b data evaluating botensilimab (BOT), an Fc-enhanced anti-CTLA-4 antibody, in combination with balstilimab (BAL), an

Approved for use before surgery based on DESTINY-Breast11 Phase III trial Approved for use following surgery based on DESTINY-Breast05 Phase III trial Two new indications bring AstraZeneca and Daiichi Sankyo’s ENHERTU into curative-intent setting, reinforcing its role across stages of HER2-positive breast cancer AstraZeneca and Daiichi Sankyo’s ENHERTU® (fam-trastuzumab deruxtecan-nxki) has been approved by the US Food and Drug Administration (FDA) for both the neoadjuvant and adjuvant treatmen

Extended follow-up data from the phase 3 study (20 months after reported topline data, median follow-up 58 months) confirmed a statistically significant and clinically meaningful improvement in prostate cancer–specific disease-free survival (DFS) of 39% after aglatimagene administration compared to placebo, reinforcing the potential of aglatimagene to reduce the risk of tumor recurrence in men receiving radiotherapy for localized disease. Clinical benefit demonstrated in the intention-to treat

Patients treated with corabotase showed a rapid onset of action of 0.84 days and peak effect statistically superior to placebo At Week 24, 60.8% of patients treated with corabotase experienced clinically significant sustained duration of effect vs placebo and vs Dysport, defined as a score of “none” or “mild” of line severity Patient satisfaction scores at Week 24 were 82.8% Corabotase is currently being evaluated as an investigational treatment in aesthetic indications 16 May 2026 – Ipsen (Eur

With the help of DNA testing company Natera and its personalized molecular residual disease (MRD) blood test Signatera, Roche’s PD-L1 inhibitor Tecentriq has chalked up its eleventh U.S. indication in the form of a new bladder cancer approval. Tecentriq and subcutaneous Tecentriq Hybreza can now be used as an adjuvant treatment for adult patients with muscle-invasive bladder cancer (MIBC) who have circulating tumor DNA molecular residual disease (ctDNA MRD) following a cystectomy, as identified

Achieved primary endpoint with high statistical significance; 93% of patients achieved microdystrophin expression above 10% (pStatistically significant correlation between RGX-202 microdystrophin expression and functional improvement (NSAA n=9), supporting validity of surrogate endpoint Well-tolerated, differentiated safety profile Company preparing for potential accelerated approval in 2027 Webcast to be held at 8:00 a.m. ET today May 14, 2026 -- REGENXBIO Inc. (Nasdaq: RGNX) announced positiv

BeOne Medicines Ltd. (“BeOne”) (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval to BEQALZI™ (bee-KAHL-zee; sonrotoclax), a foundational, next-generation BCL2 inhibitor, for the treatment of adult patients with relapsed or refractory (R/R) mantle cell lymphoma (MCL), after at least two lines of systemic therapy, including a Bruton’s tyrosine kinase (BTK) inhibitor. BEQALZI was desi

-DMD preclinical data support candidate declaration for GB703, a potential DMD gene therapy designed to broaden mutation coverage and improve muscle delivery -SMA1 preclinical data support the ongoing CHARISMA Phase 1/2 clinical trial for SMA1, which is advancing on schedule May 14, 2026 -- Gemma Biotherapeutics ("GEMMABio"), a clinical‑stage, global, genetic medicines company, today announced the presentation of preclinical data supporting candidate declaration for GB703, a novel, potential ge

May 14, 2026 -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its research collaborators presented positive preclinical data on the Company's diabetes gene therapy drug candidate at the 2026 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting. The collaborators presented preclinical data demonstrating that the diabetes gene ther

Tessera Therapeutics has created an experimental gene editing drug for sickle cell disease that could compete with commercial cell therapies but is delivered as an infusion — no complex cell engineering or chemotherapy preconditioning required. The closely watched and well-funded startup said that a single infusion of its experimental therapy edited the hemoglobin gene, which is mutated in the disease, in 85% of red blood cells in monkeys. That level of editing is almost triple the 30% threshol